Previous 10 | Next 10 |
Two sample Breakout Stocks for Week 52 with better than 10% short-term upside potential and a Dow stock pick. This past week, two stocks beat 10% peak gains in FLGT +19.1% and DYAI +13.8% with Momentum Gauge® values improving through the week. Following the Daily Momentum Gau...
REDWOOD CITY, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the launch of its Codex® HiTemp Reverse Transcriptase for use in one-step quantitative reverse transcrip...
For 2022, I am going to focus on those companies poised to benefit from the tragic COVID-19 pandemic. I maintain that SARS-CoV-2 will be with us for a long time. As for the proposed drug price legislation in BBBA, it would impact biologics (high cost medications) only near the end of ...
REDWOOD CITY, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that two of the Company’s wholly owned biotherapeutic programs, CDX-6512 for the treatment of homocyst...
REDWOOD CITY, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointments of Karen Frechou-Armijo as Senior Vice President, Human Resources and Asli Aras, Ph.D., as V...
REDWOOD CITY, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced two oral presentations highlighting its therapeutic discovery programs to develop potential treatments fo...
Codexis shares jump (CDXS +18.5%) after the company posted third-quarter revenue and profit that beat Wall Street estimates. Quarterly revenue nearly doubled to $36.77M, beating analysts' average estimate by $8.25M. Product revenues increased 242% to $28.7M in Q3’21, primarily driven b...
The following slide deck was published by Codexis, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Codexis, Inc. 2021 Q3 - Results - Earnings Call Presentation
ReWalk Robotics (NASDAQ:RWLK) +44% FDA awards breakthrough device designation to the ReWalk reBoot Soft exo-suit Borr Drilling (NYSE:BORR) +31% on Q3 earnings. Assertio Holdings (NASDAQ:ASRT) +22% on Q3 earnings. Ontrak (NASDAQ:OTRK) +20% on Q3 earnings. Big...
Image source: The Motley Fool. Codexis Inc (NASDAQ: CDXS) Q3 2021 Earnings Call Nov 4, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Codexis Inc (CDXS) Q3 2021 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second quarter of 2024 on Thursday, August 8, 2024, following the close of market. Codexis management will ...
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company’s investigational Fabry and Pompe disease compounds. Under...
2024-05-30 07:30:04 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for CDXS on May 30, 2024 06:15AM ET. CDXS was trading at $3.19 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy rec...